Based on this, the phase III SPOTLIGHT and GLOW trials selected patients with advanced HER2- GC/GEJ and claudin18.2 expression of 2 + /3 + by IHC in ≥ 75% of tumor tissue to receive either CAPOX + zolbetuximab (GLOW) or FOLFOX + zolbetuximab (SPOTLIGHT) in the first-line setting [81, 82]. The gene discussed is ERBB2; the disease is neoplasm.